Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Abstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐p...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophia Stock, Veit L. Bücklein, Viktoria Blumenberg, Giulia Magno, Alica‐Joana Emhardt, Alessandra M. E. Holzem, David M. Cordas dos Santos, Christian Schmidt, Stefanie Grießhammer, Lisa Frölich, Sebastian Kobold, Michael vonBergwelt‐Baildon, Kai Rejeski, Marion Subklewe
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70062
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/hem3.70062

Similar Items